GLPwatch
Bydureon for Fertility ("Ozempic babies")
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCBydureon (exenatide) is not FDA-approved for improving fertility. Research in mice suggests it may reduce obesity-related harm to sperm quality, while a study in women with PCOS found no significant improvement in pregnancy rates or outcomes with exenatide compared to metformin.
AI summary of the sources below.
| Drug | Bydureon (exenatide) |
|---|---|
| Condition | Fertility ("Ozempic babies") |
| Approval status | Investigational / off-label |
| Research papers | 3 |
Bydureon is not FDA-approved for fertility ("ozempic babies"); the research below reflects investigational or off-label study only.
Research on exenatide for fertility ("ozempic babies") (3)
- GLP-1 Receptor Agonist Exenatide Attenuates the Detrimental Effects of Obesity on Inflammatory Profile in Testis and Sperm Quality in Mice.
- Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.
- Exenatide improves cisplatin induced ovarian damage through NLRP3, Nrf-2, and TLR4 pathways.